Mevacor Study Comparing Rx And OTC Use Is Among FDA Panel Suggestions
Executive Summary
Merck should conduct a head-to-head comparison study of Mevacor in prescription and over-the-counter settings, Endocrinologic and Metabolic Drugs Advisory Committee member William Tamborlane, MD, said during a review of Merck's OTC switch application for Mevacor.
You may also be interested in...
Mevacor Rx-To-OTC Switch Needs More Study, Committees Advise
J&J/Merck's proposed nonprescription statin Mevacor Daily is likely to require more research to reach over-the-counter status after a joint FDA advisory committee found flaws in the sponsors' actual-use CUSTOM study
Mevacor Rx-To-OTC Switch Needs More Study, Committees Advise
J&J/Merck's proposed nonprescription statin Mevacor Daily is likely to require more research to reach over-the-counter status after a joint FDA advisory committee found flaws in the sponsors' actual-use CUSTOM study
Zocor OTC Switch Sought In U.K.; Merck’s First Choice For U.S. Is Mevacor
Merck continues to favor Mevacor as its primary OTC switch candidate for the U.S. statin market despite a favorable recommendation by the British Department of Health to sell Zocor over the counter in the U.K